SLC5A2 and diabetes mellitus: Beyond lowering blood glucose levels and inducing weight loss in individuals with type 2 diabetes mellitus, sodium–glucose cotransporter 2 (SGLT2) inhibitors are associated with protective renal and cardiovascular effects.